Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Barex is a brand of macrogol 3350 (polyethylene glycol 3350) developed and marketed by Laboratorio Dominguez in Argentina. It is an osmotic laxative used for the treatment of occasional or chronic constipation and for bowel cleansing (colon preparation) prior to diagnostic, endoscopic, or surgical procedures. The product line includes several formulations: Barex Unipeg (pure macrogol 3350), Barex 70 and Barex S (macrogol 3350 with electrolytes to maintain isotonic balance), Barex Plus (macrogol 3350 with electrolytes and ascorbic acid/sodium ascorbate), and Barex Kit (which combines macrogol 3350 with bisacodyl tablets). Macrogol 3350 is a high molecular weight polymer that is minimally absorbed from the gastrointestinal tract and acts physically by binding water molecules, increasing stool volume and softening feces to promote peristalsis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol 3350.